2021.
-
- Apr.15.2021 R & D
- Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
-
- Apr.14.2021 R & D
- ONO Submits Supplemental Application for Approval for Opdivo® (Nivolumab) to Expand the Use for Cancer of Unknown Primary in Japan
-
- Apr.12.2021 R & D
- Neoadjuvant Opdivo® (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
-
- Apr.09.2021 R & D
- Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
-
- Apr.05.2021 Corporate
- Announcement on Changes of Members of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers
-
- Mar.31.2021 R & D
- ONO Submits Supplemental Application for Approval for Opdivo® (Nivolumab) to Expand its Use as Adjuvant Therapy of Resected Urothelial Cancer in Japan
-
- Mar.30.2021 R & D
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
-
- Mar.29.2021 Sustainability
- ONO Received “Osaka Governor's Award” of the
Osaka Stop Global Warming Awards for FY2020
-
- Mar.26.2021 R & D
- Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma Meets Primary Endpoint of Progression-Free Survival
-
- Mar.26.2021 R & D
- ONO Joins the University of California Drug Discovery Consortium
-
- Mar.23.2021 R & D
- Ono and Seikagaku Announce a Manufacturing and Marketing Approval in Japan for JOYCLU® 30mg Intra-articular Injection, a Joint Function Improvement Agent, for the Indication of Osteoarthritis (Knee Joint and Hip Joint)
-
- Mar.01.2021 Licensing
- ONO Entered License Agreement with PeptiDream Inc. on Automated Peptide Discovery Platform System (PDPS) Platform
-
- Mar.01.2021 R & D
- Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
-
- Feb.26.2021 R & D
- Opdivo® (Nivolumab) Intravenous Infusion Approved for First–Line Treatment of Advanced or Recurrent Non-Small Cell Lung Cancer in Combination Therapy in Taiwan
-
- Feb.26.2021 R & D
- ONO Entered Sponsorship Agreements with LabCentral and MBC BioLabs
-
- Feb.18.2021 R & D
- ONO Submits Supplemental Application for Approval for Opdivo® (Nivolumab) to Expand the Use for Adjuvant Therapy of Resected Esophageal Cancer in Japan
-
- Feb.17.2021 Corporate
- Statement concerning Prosecution of Employees
-
- Feb.09.2021 R & D
- Adjuvant Treatment with Opdivo (nivolumab) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival in Patients with Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial
-
- Feb.09.2021 R & D
- OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the Phase 3 CheckMate -9ER Trial
-
- Feb.02.2021 Licensing
- ONO enters into License Agreement with Ribon Therapeutics for the Development and Commercialization of RBN-2397, a PARP7 Inhibitor, in Japan, South Korea, Taiwan and ASEAN Countries
-
- Feb.01.2021 Management / Finance
- Announcement on Financial Results for FY2020 3Q
-
- Feb.01.2021 Corporate
- Notice concerning the Establishment of Ono Pharma Healthcare Co., Ltd.
-
- Feb.01.2021 Products
- ONO Announces Transfer of the Manufacturing and Marketing Approval Authorization for Kinedak Tablets to Alfresa Pharma Corporation
-
- Jan.29.2021 Corporate
- Statement concerning Arrest of Employees
-
- Jan.28.2021 R & D
- ONO Submits Supplemental Application for Approval of Opdivo® (Nivolumab) to Expand the Use for Treatment of Pediatric Patients with Recurrent or Refractory Classical Hodgkin Lymphoma in Japan
-
- Jan.25.2021 R & D
- U.S. Food and Drug Administration Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
-
- Jan.22.2021 R & D
- ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
-
- Jan.21.2021 R & D
- U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer
-
- Jan.21.2021 R & D
- U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
-
- Jan.12.2021 Corporate
- Notice on the Adopter of the "Osamu Hayaishi Memorial Scholarship for Study Abroad" of the FY2021 Japanese Biochemical Society
-
- Jan.07.2021 R & D
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
-
- Jan.07.2021 R & D
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line reatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
-
- Jan.05.2021 Corporate
- Notice on renewal of Ono’s official corporate website